SCN9A Antibodies

Background

The SCN9A gene encodes the α subunit of the voltage-gated sodium channel Nav1.7, a protein mainly distributed in nosgenic neurons of the peripheral nervous system. Its function is to generate and transmit action potentials by mediating the influx of sodium ions, playing a core regulatory role in the perception and conduction of pain signals. Gation-acquired mutations in this gene can lead to hereditary pain syndromes such as primary erythematous limb pain, while loss-of-function mutations may cause congenital anaesthesia, which is manifested as a loss of perception of noxious stimuli. Due to its specific expression in the pain pathway, the Nav1.7 channel has become an important target for the development of analgesic drugs. The research on its structure and function has greatly promoted the understanding of the molecular mechanism of pain and the development of targeted treatment strategies.

Structure Function Application Advantage Our Products

Structure of SCN9A

The Nav1.7 sodium channel protein encoded by the SCN9A gene is a large transmembrane protein of approximately 220 kDa. This protein is composed of four highly similar domains (I-IV), each of which contains six transmembrane segments (S1-S6), among which the S4 fragment serves as a voltage sensor responsible for voltage-dependent activation of the channel.

Species	Human	Mouse	Rat	Bovine
Molecular Weight (kDa)	220	219.5	219.8	220.2
Primary Structural Differences	Contains 2016 amino acids	The C-end is relatively short	There are variations in the extracellular loop region	Domain III has specific mutations

The four domains of this protein are connected by intracellular junction rings, jointly forming a central pore region responsible for the selective permeation of sodium ions. The P ring between S5 and S6 constitutes the narrowestern part of the pore channel, and its unique amino acid sequence (Asp-Glu-Lys-Ala) determines the high selectivity of the channel for sodium ions. The S4 fragment of each domain is rich in positively charged arginine residues, which undergo conformational shift when the membrane potential changes, driving the activation gating of the channel.

Fig. 1 Procheck-RAMACHANDRAN plot of the native SCN9A predicted model.¹

Key structural properties of SCN9A:

Tetramer transmembrane structure
Voltage sensing module
Selective filter

Functions of SCN9A

The Nav1.7 sodium ion channel encoded by the SCN9A gene plays a core role in pain signal transduction, and its functional characteristics are as follows:

Function	Description
Initiation of action potential	In sensory neurons, it is responsible for triggering and amplifying action potentials, serving as the starting point of pain signals.
Pain signal transduction	Convert harmful stimuli into electrical signals to achieve the transmission of pain information from the periphery to the central nervous system.
Regulation of pain sensitization	Involved in inflammatory and neuropathy pain sensitization process, enhances the reactivity of neurons to stimuli.
Hurt perception integration	Integrate multiple noxious stimulus signals and regulate the dynamic changes of pain threshold.
Hereditary pain disorders	Functional acquisition mutations lead to paroxysmal severe pain, while functional loss mutations cause congenital anaesthesia.

The activation characteristics of the Nav1.7 channel exhibit a voltage-dependent pattern of rapid activation and slow deactivation. This feature enables it to precisely regulate neuronal excitability and play a key role as a "molecular gate" in the pain pathway.

Applications of SCN9A and SCN9A Antibody in Literature

1. Waheed, Sana, et al. "Identification and In-Silico study of non-synonymous functional SNPs in the human SCN9A gene." PloS one 19.2 (2024): e0297367. https://doi.org/10.1371/journal.pone.0297367

The article indicates that specific single nucleotide polymorphisms of the SCN9A gene may impair sodium channel function. The research identified key pathogenic loci such as L1802P through bioinformatics methods, laying a foundation for the study of disease mechanisms and targeted therapy.

2. Fasham, James, et al. "No association between SCN9A and monogenic human epilepsy disorders." PLoS genetics 16.11 (2020): e1009161. https://doi.org/10.1371/journal.pgen.1009161

The article indicates that the SCN9A gene was once included in the epilepsy detection panel, but new evidence shows that its related variations are frequently present in healthy people and have no relation to epilepsy. To avoid misdiagnosis, it is recommended to remove it from clinical testing.

3. Gutierrez‐Quintana, Rodrigo, et al. "SCN9A variant in a family of mixed breed dogs with congenital insensitivity to pain." Journal of veterinary internal medicine 37.1 (2023): 230-235. https://doi.org/10.1111/jvim.16610

The article indicates that researchers have diagnosed congenital painless syndrome in a litter of mixed-breed dogs and found that it was caused by a novel homozygous mutation in the SCN9A gene. This spontaneous case is the first reported in domestic animals.

4. Ghanty, Ismael, et al. "SCN9A should not be considered an epilepsy gene; Refuting a gene–disease association." Epilepsia (2025). https://doi.org/10.1111/epi.18474

This study systematically evaluated the association between the SCN9A gene and epilepsy and found that the vast majority of "epileptogenic" variations lack evidence and even occur in healthy individuals. The results show that SCN9A is not an epileptic gene and should be removed from the detection panel.

5. Faux, Pierre, et al. "Neanderthal introgression in SCN9A impacts mechanical pain sensitivity." Communications Biology 6.1 (2023): 958. https://doi.org/10.1038/s42003-023-05286-z

Research has found that three specific variations (M932L, V991L, D1908G) in the SCN9A gene, which originated from Neanderthals, are common in the Latin American population and have been confirmed to be significantly associated with a reduced mechanical pain threshold.

Creative Biolabs: SCN9A Antibodies for Research

Creative Biolabs specializes in the production of high-quality SCN9A antibodies for research and industrial applications. Our portfolio includes monoclonal antibodies tailored for ELISA, Flow Cytometry, Western blot, immunohistochemistry, and other diagnostic methodologies.

Custom SCN9A Antibody Development: Tailor-made solutions to meet specific research requirements.
Bulk Production: Large-scale antibody manufacturing for industry partners.
Technical Support: Expert consultation for protocol optimization and troubleshooting.
Aliquoting Services: Conveniently sized aliquots for long-term storage and consistent experimental outcomes.

For more details on our SCN9A antibodies, custom preparations, or technical support, contact us at email.

Reference

Waheed, Sana, et al. "Identification and In-Silico study of non-synonymous functional SNPs in the human SCN9A gene." PloS one 19.2 (2024): e0297367. https://doi.org/10.1371/journal.pone.0297367